clinical trial · NCT05157243
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
Romark Laboratories L.C.·phase3·withdrawn
COVID-19NitazoxanideVitamin Super-B ComplexPlaceboStandard of Care
brief summary
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes. Each participant will be followed for approximately 28 days.
started
Aug 1, 2024
primary completion
May 1, 2025
completion
May 1, 2025
last updated
Sep 24, 2024
official title
Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol